Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $1 | $1 |
| SG&A Expenses | $1 | $0 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $1 | $0 | $1 | $1 |
| Operating Income | -$1 | -$0 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $23 | $0 | $0 | $0 |
| Net Income | -$24 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -1.64 | -0.017 | -0.02 | -0.027 |
| % Growth | -9,720.4% | 14.4% | 28.8% | – |
| EPS Diluted | -1.64 | -0.017 | -0.02 | -0.027 |
| Weighted Avg Shares Out | 14 | 14 | 14 | 14 |
| Weighted Avg Shares Out Dil | 14 | 14 | 14 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$1 | $0 | -$1 | -$1 |
| % Margin | – | – | – | – |